Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Free Cash Flow (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Free Cash Flow data on record, last reported at -$15.4 million in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 63.75% year-over-year to -$15.4 million; the TTM value through Dec 2025 reached -$61.2 million, down 175.95%, while the annual FY2025 figure was -$61.2 million, 175.95% down from the prior year.
  • Free Cash Flow reached -$15.4 million in Q4 2025 per MRVI's latest filing, up from -$18.1 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $161.6 million in Q2 2022 and bottomed at -$42.5 million in Q4 2024.
  • Average Free Cash Flow over 5 years is $43.1 million, with a median of $25.4 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: skyrocketed 1684.35% in 2021, then crashed 371.65% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at $65.8 million in 2021, then increased by 27.75% to $84.0 million in 2022, then tumbled by 110.72% to -$9.0 million in 2023, then plummeted by 371.65% to -$42.5 million in 2024, then skyrocketed by 63.75% to -$15.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$15.4 million in Q4 2025, -$18.1 million in Q3 2025, and -$13.1 million in Q2 2025.